All four CGRP monoclonal antibodies for migraine not only reduce headache days but meaningfully improve quality of life, disability, and work productivity based on patient-reported outcomes.
First migraine-specific preventivesAll four CGRP-mAbs improved quality of life, disability, and work productivity — not just headache frequency — in clinical trials
What the researchers found
CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) — the first migraine-specific preventive treatments — improve quality of life, reduce disability, and boost workplace productivity in migraine patients. Clinical trial data using patient-reported outcomes consistently showed improvements beyond just reducing headache days.
All four CGRP-mAbs achieved their primary endpoints of reducing monthly headache days and demonstrated meaningful impacts on daily functioning, global impression of change, and the overall burden of migraine on patients' lives.
Why it matters
Migraine affects hundreds of millions of people worldwide and is one of the leading causes of disability. Before CGRP-mAbs, preventive treatments were all repurposed from other conditions (blood pressure drugs, antidepressants, seizure medications) with significant side effects. These were the first drugs designed specifically for migraine prevention, and this review shows they improve not just headache frequency but the overall quality of patients' lives — a distinction that matters enormously for real-world patient care.
The numbers in context
4 CGRP-mAbs reviewed: erenumab, fremanezumab, galcanezumab, eptinezumab · FDA and EMA approved · Improved: headache days, disability scores, QoL, workplace productivity, patient global impression
How the study worked
Narrative review of clinical trial data for all four FDA/EMA-approved CGRP monoclonal antibodies, focusing on patient-reported outcomes including quality of life, disability measures, workplace productivity, and global impression of change. Reviewed data from trials in both episodic and chronic migraine populations.
Who was studied
Migraine patients (episodic and chronic) from clinical trials of four CGRP monoclonal antibodies
What this study cannot tell us
Based on clinical trial populations that may not fully represent real-world migraine patients. Patient-reported outcomes can be subjective and influenced by placebo effects. Long-term quality of life data beyond the trial periods was limited at the time of publication. Comparative effectiveness between the four CGRP-mAbs was not directly assessed.
How to read the evidence
This review synthesizes data from multiple randomized controlled trials of FDA/EMA-approved drugs, representing strong clinical evidence. The patient-reported outcomes complement the primary efficacy endpoints from these trials.
When this study was published
Published in 2019, shortly after all four CGRP-mAbs gained approval. Since then, extensive real-world evidence has confirmed the quality-of-life benefits described here, and the CGRP-targeting drug class has expanded to include oral gepants.
The bigger picture
The approval of CGRP-mAbs marked a paradigm shift in migraine treatment — from repurposed drugs to targeted peptide-pathway therapies. This review emphasized that clinical trials should measure what matters to patients (quality of life, daily functioning) not just biological endpoints (headache days). Since publication, real-world data has confirmed these quality-of-life improvements, and newer CGRP-pathway drugs (including oral gepants) have further expanded options.
Questions still open
- Do the quality-of-life improvements seen in clinical trials hold up in diverse real-world patient populations?
- Which of the four CGRP-mAbs provides the best quality-of-life improvement when compared head-to-head?
- How do CGRP-mAb quality-of-life outcomes compare to newer oral CGRP receptor antagonists (gepants)?
Common questions
What is CGRP and why does blocking it help migraines?
Do these drugs cure migraines or just reduce them?
Read the original research
How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? A patient's perspective.
Current opinion in neurology, 32(3), 395-404
Citation
Torres-Ferrus, Marta; Alpuente, Alicia; Pozo-Rosich, Patricia. (2019). How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? A patient's perspective.. Current opinion in neurology, 32(3), 395-404. https://doi.org/10.1097/WCO.0000000000000689